Introduction {#s1}
============

Respiratory complex I is a \~1 MDa membrane protein complex with key functions in aerobic energy metabolism ([@bib26]; [@bib46]). Fourteen central subunits are conserved from bacteria to mammals. Mitochondrial complex I contains in addition around 30 accessory subunits. The energy released in the electron transfer reaction from NADH to ubiquinone is utilized to pump protons across the inner mitochondrial membrane or the bacterial cell membrane. The electrochemical gradient established by redox-coupled proton translocation drives ATP synthesis. Dysfunction of complex I is implicated in a number of neuromuscular and degenerative diseases ([@bib40]). In myocardial infarction, complex I releases detrimental reactive oxygen species (ROS) that contribute to reperfusion injury ([@bib15]). The reversible conversion of the active A-form of complex I into the deactive D-form (A/D transition) ([@bib31]) is thought to minimize ROS formation.

X-ray structures of bacterial complex I ([@bib6]) and of the mitochondrial complex I from the aerobic yeast *Yarrowia lipolytica* ([@bib51]) were solved at 3.3 and 3.6 to 3.9 Å resolution, respectively. Recent technical progress has permitted the structure of mammalian complex I by itself or as part of a supercomplex to be determined at 3.3 to 4.2 Å resolution by electron cryo-microscopy (cryo-EM) ([@bib50]; [@bib21]; [@bib22]; [@bib47]; [@bib35]; [@bib23]; [@bib9]; [@bib2]). Even though the structure of complex I is now well-characterized, essential mechanistic details of the catalytic cycle remain elusive, and conflicting models for the A/D transition have recently been proposed ([@bib51]; [@bib9]). There is general agreement that the reduction of ubiquinone at a position above the membrane bilayer triggers and drives proton translocation, but it is not clear how this works. We hypothesized that the power stroke generated during ubiquinone reduction results from a concerted rearrangement of its binding site and the surrounding protein region, driven by the stabilization of anionic ubiquinone intermediates ([@bib51]). This mechanism implies a cycling between two alternating ubiquinone binding sites during turnover, one of which (the E-state) selectively allows reduction and the other (the P-state), protonation of the ubiquinone headgroup. The associated conformational changes are thought to polarize key residues at the start of a chain of conserved acidic and basic residues extending into and along the membrane arm, thus creating an electrostatic pulse ([@bib19]) driving the proton pumping modules of complex I. To gain insight into the mode of ubiquinone binding and the conformation of its binding site during catalysis, we used cryo-EM to analyse the structure of mitochondrial complex I from the aerobic yeast *Y. lipolytica* captured during steady-state turnover and in the deactive form.

Results {#s2}
=======

Cryo-EM structure of *Y. lipolytica* complex I in the deactive state {#s2-1}
--------------------------------------------------------------------

A cryo-EM map of complex I purified from *Y. lipolytica* was obtained from 124,626 particle images and refined to 4.3 Å overall resolution ([Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). Central parts of the molecule were significantly better resolved ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). The final model of 42 subunits was 88% complete and contained 7515 fitted residues ([Figure 4](#fig4){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). The cryo-EM structure of complex I agrees well (r.m.s.d. of 1.768 Å for central subunits) with the previously determined X-ray structure in the deactive state, which was however much less complete with only 4979 residues fitted ([Figure 5](#fig5){ref-type="fig"}). Whereas cryo-EM of mammalian complex I resolved several different conformations ([@bib50]; [@bib21]), we observed only one major class, indicating that the preparation of *Y. lipolytica* complex I was homogeneous and in a uniform state ([Figure 1](#fig1){ref-type="fig"}).

![Image processing and two-dimensional classification of particle images.\
Electron densities of complex I in the deactive state and under turnover conditions are light blue and magenta. About 30% of the particles belong to a subclass (yellow) which contains the accessory sulfur transferase subunit ST1 known to be bound substoichiometrically to *Y. lipolytica* complex I ([@bib16]).](elife-39213-fig1){#fig1}

![Local resolution and Fourier shell correlation (FSC) curves of (**A**) deactive complex I and (**B**) complex I under steady-state turnover conditions.\
Left: cryo-EM maps of complex I analysed by ResMap ([@bib34]) coloured according to local resolution. Right: FSC plots of final masked and refined cryo-EM maps. The map resolution is indicated by the point where the curve crosses the 0.143 threshold ([@bib42]).](elife-39213-fig2){#fig2}

![Cryo-EM map of deactive complex I with fitted models.\
(**A**) Selected regions of the matrix domain. (**B**) A horizontal cross-section through the membrane arm shows TMH fits. (**C**) A region of the accessory LYR protein subunit NB4M ([@bib4]); the acyl chain appended to the phosphopantetheine group of the adjacent acyl carrier protein ACPM1 inserts into the interior of NB4M. Cofactor and acyl chain are drawn as ball-and-stick model.](elife-39213-fig3){#fig3}

![Cryo-EM structure of respiratory complex I from *Y. lipolytica*.\
(**A**) Side view; (**B**) view from peripheral arm; central subunits (labelled, solid) and accessory subunits (transparent, compare [Figure 8](#fig8){ref-type="fig"}) are shown.](elife-39213-fig4){#fig4}

![Cryo-EM and X-ray structures of deactive complex I are consistent.\
(**A**) With 42 assigned subunits (colour coded as in [Figures 4](#fig4){ref-type="fig"} and [8](#fig8){ref-type="fig"}) and 7515 residues the cryo-EM structure is significantly more complete than the X-ray structure (**B**) with 15 assigned subunits and 4979 residues (colour coded as in (**A**). Unassigned parts of the model are grey. Red arrows indicate subunits NI8M, NUYM, NUZM, N7BM, NUMM, cofactors FMN (51 kDa subunit) and NADPH (NUEM subunit) that are missing or incomplete in the X-ray structure. (**C**) X-ray structure of deactive complex I from *Y. lipolytica* ([@bib51]) (grey) overlaid with the cryo-EM structure of deactive *Y. lipolytica* complex I (blue).](elife-39213-fig5){#fig5}
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###### Data collection, refinement and model statistics.

  --------------------------------------------------------------------------------------
                                  Deactive                       steady-state turnover
  ------------------------------- ------------------------------ -----------------------
  Data collection\                \                              \
  Microscope                      FEI Tecnai Polara              FEI Titan Krios

  Camera                          Gatan K2 Summit                Falcon III

  Voltage (kV)\                   300\                           300\
  Nominal magnification\          200,000x\                      75,000x\
  Calibrated pixel size (Å)       1.09                           1.053

  Total exposure (e^-^/Å^2^)      60.5                           30.7--40.7

  Exposure rate (e^-^/pixel/s)\   9\                             0.4\
  Number of frames                40                             81

  Defocus range (μm)              1.5--3.0                       1.5--4.5

  Image processing\               \                              \
  Motion correction software      *MotionCor2*                   *MotionCor2*

  CTF estimation software         *CTFFIND4*                     *Gctf*

  Particle selection software     *EMAN* boxer and *RELION2.1*   *RELION2.1*

  Initial/final micrographs       3,110/3,110                    5,964/5,650

  Particles selected              271,443                        273,581

  Applied *B*-factor (Å^2^)       −142                           −215

  Final resolution (Å)            4.3                            4.5

  Refinement statistics\          \                              
  Modeling software               *COOT, PHENIX*                 

  Number of residues              7515                           

  Map CC (whole unit cell)        0.786                          

  RMS deviations\                 0.0099                         
  Bond-lengths (Å)                                               

  Bond-angles (°)                 1.52                           

  Av. B-factor (Å^2^)             151.46                         

  Ramachandran plot\              \                              
  Outliers (%)                    0.74                           

  Allowed (%)                     13.43                          

  Favoured (%)                    85.83                          

  Rotamer outliers (%)            0.71                           

  Molprobity score                2.11                           

  All-atom clashscore             8.55                           

                                                                 

  PDB ID                          6GCS                           
  --------------------------------------------------------------------------------------
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###### Composition of subunits.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Subunit                             human/bovine    Chain   Total residues/\   Modelled with\   Modelled as\   \[%\] residues\   \[%\] with\   \[%\]\
                                                              range built        side chains      poly-alanine   modelled          side chains   unknown
  ----------------------------------- --------------- ------- ------------------ ---------------- -------------- ----------------- ------------- ---------
  central subunits                                                                                                                               

  NUAM                                NDUFS1/\        A       694/\              1--691           0              99                99            1
                                      75 kDa                  1--691                                                                             

  NUBM                                NDUFV1/\        B       470/\              15--437          437--457       95                90            6
                                      51 kDa                  15--457                                                                            

  NUCM                                NDUFS2/\        C       444/\              58--67\          28--57\        93                85            7
                                      49 kDa                  28--443            77--443          68--76                                         

  NUGM                                NDUFS3/\        G       251/\              30--189          1--29\         92                64            8
                                      30 kDa                  1--232                              190--232                                       

  NUHM                                NDUFV2/\        H       215/\              23--187          3--22          86                78            14
                                      24 kDa                  3--187                                                                             

  NUIM                                NDUFS8/\        I       198/\              26--198          19--26         91                87            9
                                      TYKY                    19--198                                                                            

  NUKM                                NDUFS7/\        K       183/\              15--183          0              92                92            8
                                      PSST                    15--183                                                                            

  NU1M                                NU1M/\          1       341/\              1--179\          180--183\      100               91            0
                                      ND1                     1--340             184--205\        206--216\                                      
                                                                                 217--251\        252--267                                       
                                                                                 268--340                                                        

  NU2M                                NU2M/\          2       469/\              1--25\           26--52\        96                80            4
                                      ND2                     1--85\             53--85\          416--465                                       
                                                              99--465            99--415                                                         

  NU3M                                NU3M/\          3       128/\              1--34\           119--124       81                77            19
                                      ND3                     1--34\             49--118                                                         
                                                              49--124                                                                            

  NU4M                                NU4M/\          4       486/\              85--189\         7--84\         98                70            2
                                      ND4                     7--481             201--434         190--200\                                      
                                                                                                  435--481                                       

  NU5M                                NU5M/\          5       655\               28--436\         5--27\         98                75            2
                                      ND5                     5--479\            457--474\        437--456\                                      
                                                              489--652           568--592\        475--479\                                      
                                                                                 614--652         489--567\                                      
                                                                                                  593--613                                       

  NU6M                                NU6M/\          6       185\               2--77\           78--159        99                55            1
                                      ND6                     2--184             160--184                                                        

  NULM                                NULM/\          L       89\                1--86            0              97                97            3
                                      ND4L                    1--86                                                                              

  accessory subunits peripheral arm                                                                                                              

  NUEM                                NDUFA9/\        E       355\               17--334          0              82                82            18
                                      39 kDa                  17--334                                                                            

  NUFM                                NDUFA5/\        F       136\               34--131          13--33         88                72            12
                                      B13                     13--131                                                                            

  NUMM                                NDUFS6/\        M       119\               43--117          13--42         88                75            12
                                      13 kDa                  13--117                                                                            

  NUYM                                NDUFS4/\        Y       137\               19--133          0              84                84            16
                                      18 kDa                  19--133                                                                            

  NUZM                                NDUFA7/\        Z       182\               0                30--166        75                0             25
                                      B14.5a                  30--166                                                                            

  N7BM                                NDUFA12/B17.2   h       137\               6--135           0              95                95            5
                                                              6--135                                                                             

  NB4M                                NDUFA6/\        P       123\               3--118           0              94                94            6
                                      B14                     3--118                                                                             

  ACPM1                               NDUFAB1/SDAP    O       84\                4--80            0              92                92            8
                                                              4--80                                                                              

  NI8M                                NDUFA2/\        f       86\                5--84            0              93                93            7
                                      B8                      5--84                                                                              

  Accessory subunits P~P~ module                                                                                                                 

  NUPM                                Ndufa8/\        U       171\               16--142          10--15\        92                74            8
                                      pgiv                    10--167                             143--167                                       

  NUJM                                NDUFA11/B14.7   J       197\               18--133          134--157       71                59            29
                                                              18--157                                                                            

  NB6M                                NDUFA13/B16.6   W       122\               14--120          3--13          97                88            3
                                                              3--120                                                                             

  NIPM                                NDUFS5/\        9       88\                14--66           08--13         67                60            33
                                      15 kDa                  8--66                                                                              

  NUXM                                -/-             X       168\               72--96           4--71\         70                15            30
                                                              4--120                              97--120                                        

  NI9M                                NDUFA3/\        g       66\                3--62                           91                91            9
                                      B9                      3--62                                                                              

  NIMM                                NDUFA1/\        D       86\                1--58            59--80         93                67            7
                                      MWFE                    1--80                                                                              

  NEBM                                NDUFC2/\        b       73\                                 1--64          87                0             13
                                      B14.5b                  1--64                                                                              

  accessory subunits P~D~ module                                                                                                                 

  NESM                                NDUFB11/ESSS    S       204\                                29--187        78                0             22
                                                              29--187                                                                            

  NIAM                                NDUFB8/\        a       125\                                11--110        80                0             20
                                      ASHI                    11--110                                                                            

  NUNM                                NDUFB5/\        n       119\                                23--115        78                0             22
                                      SGDH                    23--115                                                                            

  NB2M                                NDUFB3/\        c       59\                31--49           8--30          71                32            29
                                      B12                     8--49                                                                              

  NB5M                                NDUFB4/\        j       92\                16--41           3--15\         82                27            18
                                      B15                     3--75                               42--75                                         

  NB8M                                NDUFB7/\        8       98\                3--80            81--84         84                80            16
                                      B18                     3--84                                                                              

  ACPM2                               NDUFAB1/SDAP    Q       88\                3--87            0              97                97            3
                                                              3--87                                                                              

  NIDM                                NDUFB10/PDSW    d       91\                3--91            0              98                98            5
                                                              3--91                                                                              

  NI2M                                NDUFB9/\        R       108\               6--98            99--107        94                86            6
                                      B22                     6--107                                                                             

  NUUM                                NDUFB2/\        e       89\                                 6--50          51                0             49
                                      AGGG                    6--50                                                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------

The central subunits {#s2-2}
--------------------

The overall structure of the fourteen central subunits ([Figure 4](#fig4){ref-type="fig"}) is conserved in all known complex I structures. In mammalian and *Y. lipolytica* complex I the 49 kDa subunit harbors a long N-terminal extension that runs on the matrix side to approximately the middle of the membrane arm. In *Y. lipolytica*, an N-terminal extension of the 30 kDa subunit reaches towards the attachment site of the accessory sulfur transferase subunit ST1 ([Figure 6](#fig6){ref-type="fig"}). A C-terminal sequence stretch of membrane-bound subunit ND3 extends vertically along the matrix arm, forming an elongated contact site with accessory subunit NUFM ([Figure 6](#fig6){ref-type="fig"}). Compared with the X-ray structure of *Y. lipolytica* complex I ([@bib51]) we changed the assignment of TMH4 of subunit ND6. The corresponding helices match the X-ray structure of *Thermus thermophilus* and the cryo-EM structure of *Y. lipolytica* complex I but are shifted towards the peripheral arm in mammalian complex I ([Figure 7](#fig7){ref-type="fig"}). In conjunction with the absence of TMH1-3 of ND2, this causes a conspicuous ambilateral indentation of the membrane arm of mammalian complex I that is not present in bacterial and yeast complex I.

![Docking site of accessory subunit ST1 and extensions of the 30 kDa and ND3 subunits in *Y. lipolytica* complex I.\
(**A**) ST1 (yellow) binds to N7BM (violet), NUZM (red) and the extended N-terminus of the 30 kDa subunit (blue); (**B**) N-terminal extension of the 30 kDa subunit (blue oval) and interaction of the C-terminal extension of subunit ND3 with NUFM (yellow oval).](elife-39213-fig6){#fig6}

![Overlay of membrane arm subunits of complex I from *Y. lipolytica* and *B. taurus*.\
Top view of membrane arm with subunits of the peripheral arm removed for clarity (*Y. lipolytica* blue, *B. taurus*, grey; selected subunits are coloured as indicated). The first three helices of ND2 are missing in bovine complex I and the position of TMH 4 of ND6 is different. These changes result in an incision of the membrane arm of mammalian complex I at the position of ND2. Subunit ND5 of complex I from *Y. lipolytica* has an extra C-terminal TMH (yellow asterisk \[[@bib51]\]), and TMH 1 of ND4 is oriented differently in the membrane.](elife-39213-fig7){#fig7}

The accessory subunits {#s2-3}
----------------------

We identified density for all expected 28 accessory subunits of *Y. lipolytica* complex I ([Figure 8](#fig8){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). In the membrane arm we detected density for a new accessory subunit with a single transmembrane helix (provisionally labelled X in [Figure 8](#fig8){ref-type="fig"}). With the exception of this previously unknown subunit and subunits ST1 and NUXM, all accessory subunits of *Y. lipolytica c*omplex I were assigned to corresponding subunits of mammalian complex I based on sequence alignments and structural correlation ([Table 2](#table2){ref-type="table"}). For eighteen accessory subunits the cryo-EM map showed most or almost all (59--98%) of the side chain densities ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). An overlay of eight subunits modelled completely or mainly as poly-alanine on their bovine counterparts is shown in [Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}. Subunits NESM and NUZM have prominent extra domains and the NUFM subunit carries an N-terminal extension that interacts tightly with the C-terminal extension of central subunit ND3 ([Figure 6](#fig6){ref-type="fig"}). In contrast, NI2M, NB5M and NIDM of *Y. lipolytica* are significantly smaller. We did not find any density at positions of the mammalian 42 kDa subunit (NDUFA10), the 9 kDa subunit (NDUFV3), or the MNLL (NDUFB1) subunit, consistent with the absence of their orthologs in the *Y. lipolytica* genome. The absence of the MNLL subunit correlates with a shift of the adjacent TMH1 in ND4 ([Figure 7](#fig7){ref-type="fig"}). We modelled subunit NUXM that has no correspondence in vertebrates next to the first three helices of central subunit ND2, which are absent in mammalian complex I ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). This assignment is based on the allocation of NUXM to the P~P~ module ([@bib3]), secondary structure prediction, and a short stretch of sequence with side chains. The sulfur transferase subunit ST1 was present sub-stoichiometrically as observed before ([Figure 1](#fig1){ref-type="fig"}) ([@bib16]). Based on biochemical data we had suggested that subunit N7BM anchors ST1 to the peripheral arm ([@bib30]). We now show that N7BM shares an extensive interface with ST1, and that ST1 furthermore interacts with NUZM and the N-terminal region of the 30 kDa subunit ([Figure 6](#fig6){ref-type="fig"}).

![Accessory subunits of complex I.\
Central subunits (see [Figure 4](#fig4){ref-type="fig"}) are shown in grey, accessory subunits are labelled and coloured. (**A**) Side views, (**B**) view from the matrix (left) and from the intermembrane space (right) with peripheral arm subunits removed for clarity.](elife-39213-fig8){#fig8}

Lipid molecules and an unassigned density in the interface region {#s2-4}
-----------------------------------------------------------------

Four lipid molecules were identified in the membrane arm. A prominent density in the interior of subunit ND1 towards the interface with the PSST and 49 kDa subunits was not assigned unambiguously ([Figure 9](#fig9){ref-type="fig"}). The most prominent part of this density was in direct contact with side chains of conserved Arg36^ND1^, Arg297^ND1^ and Leu200^49-kDa^, and close to the conserved Arg27^ND1^ and Arg108^PSST^. The density is remarkable because it is close to or even within the proposed access pathway by which ubiquinone enters the active site. Recent MD simulations suggested that the residues corresponding to Arg27^ND1^ and Arg108^PSST^ in bovine complex I would coordinate part of the isoprenoid side chain of ubiquinone by π-stacking of their guanidinium groups ([@bib20]). In contrast, the narrow and well-defined contact sites with Arg36^ND1^ and Arg297^ND1^ we observe are consistent with a strong ionic interaction. The density appears to be too bulky for an isoprenoid chain or even for a ubiquinone head group. We therefore suggest that the density represents the negatively charged head group of a lipid molecule. More than 60 lipid molecules per complex I were bound in our preparation as detected by mass spectrometry ([Table 3](#table3){ref-type="table"}), but at our current map resolution their densities cannot be assigned unequivocally. A lipid head group would be consistent with the complementary charges of conserved arginine residues in this area, although it would be situated at an unusual position above the membrane surface. The same density was found under turnover conditions (see below) and therefore obviously did not prevent the passage of ubiquinone to its binding site. Although a lipid molecule in this position might partly block the generally accepted ubiquinone access pathway through the portal formed by TMH1, TMH6, and helix α1--2 of ND1, it would be flexible and mobile enough to allow ubiquinone access, while keeping other hydrophilic compounds out, acting like a hydrophobic valve.

![Unassigned density (orange arrows) at the interface of subunits ND1, 49 kDa, and PSST.\
Slice of interface region of membrane and peripheral arm of complex I in the deactive state (model, cartoon representation; selected residues, stick representation; cryo-EM map, mesh). Note that the density is also present in the maps of complex I under steady-state turnover conditions.](elife-39213-fig9){#fig9}
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###### Lipid content of typical complex I preparation

  Lipid                      nmol lipid/nmol complex I
  -------------------------- ---------------------------
  phosphatidylcholine        19.3
  lyso-phosphatidylcholine   0.1
  phosphatidylethanolamine   13.3
  phosphatidylserine         0.5
  phosphatidylinositol       11.8
  cardiolipin                21.7
  Σ                          66.7

The ubiquinone binding site in the deactive state {#s2-5}
-------------------------------------------------

The ubiquinone binding and access site is essentially formed by the hydrophilic PSST and 49 kDa subunits and the membrane-intrinsic ND1 subunit ([@bib51]). In recent cryo-EM structures of deactive mammalian complex I, critical loops of the latter two subunits and of the adjacent ND3 and the accessory 39 kDa subunits were proposed to unfold, because no matching density was found ([@bib9]; [@bib2]). In our map only residues 35 -- 48 in the central part of the long TMH1-2 loop of subunit ND3 were disordered ([Figure 10](#fig10){ref-type="fig"}). In contrast to bovine complex I, we observed continuous density for the loop connecting the first two β-strands of the 49 kDa subunit and for the TMH5-6 loop of ND1. The local resolution of this region indicated some degree of flexibility, and it was therefore modelled as poly-alanine. The C-terminal domain of accessory subunit NUEM, which is supposed to have a regulatory function in the A/D transition ([@bib5]), was largely modelled with side chains, whereas the corresponding domain in the mammalian 39 kDa subunit was disordered.

![Model for subunit ND3 (yellow) and cryo-EM density (grey mesh) of subunit ND3 in the deactive state (left) and under turnover conditions (right).\
The central part of the long loop connecting TMH1 and 2 is disordered.](elife-39213-fig10){#fig10}

Cryo-EM structure under steady-state turnover conditions {#s2-6}
--------------------------------------------------------

To analyse substrate binding and structural changes during the catalytic cycle we collected cryo-EM images of complex I under turnover conditions, after adding NADH and ubiquinone to the sample. Ubiquinone is hydrophobic and even the short-chain analogue decylubiquinone (DBQ) used in this study is not soluble in aqueous buffers at sufficiently high concentrations. To avoid substrate exhaustion at 2 µM complex I concentration between adding the substrate and freezing the sample, we reduced the temperature of the reaction to 18°C and added 1 µM ubiquinol oxidase from *Vitreoscilla* sp. to recycle the ubiquinone. An increase in oxidase concentration did not increase the rate of oxygen consumption, indicating that complex I was rate-limiting and that ubiquinone oxidation was efficient. Recycling of substrate by this artificial respiratory chain sustained steady-state conditions for more than one minute, while freezing the cryo-EM sample took only 20--30 s ([Figure 11](#fig11){ref-type="fig"}).

![In vitro assay of a minimal respiratory chain of complex I and *bo*~3~-type ubiquinol oxidase.\
(**A**) Assay conducted at the substrate concentration used for cryo-EM sample preparation (2 μM complex I, 1 μM oxidase, 2 mM NADH and 200 μM DBQ at 18°C. The reaction was started by addition of NADH. (**B**) Inhibition of complex I by DQA (blue) and of the *Vitreoscilla* oxidase by CN^-^ (red).](elife-39213-fig11){#fig11}

The structure of complex I under turnover conditions indicated no overall changes compared to the deactive state. We can therefore exclude large conformational rearrangements, such as the proposed extensive movement of the two arms relative to one another ([@bib10]) ([Figure 12](#fig12){ref-type="fig"}). We also found no evidence for a piston-like movement of the long lateral helix of the membrane arm that has been proposed to couple redox chemistry to proton translocation ([@bib27]; [@bib6]). The most obvious difference was a strong additional density in the 51 kDa subunit, which was modelled as bound NADH ([Figure 13A](#fig13){ref-type="fig"}) in agreement with a previous structure of bacterial complex I ([@bib7]). A slight movement of the glycine-rich loop (Gly88-Gly91) opens the site to accommodate the substrate in this position. The pyridine ring moiety engages in a tight stacking interaction with the isoalloxazine ring of FMN to allow efficient hydride transfer. The adenine ring interacts by π-stacking with Phe92, Phe100, and Phe231 of the 51 kDa subunit. Lys228 forms a salt bridge with the pyrophosphate, and Ser325 establishes a hydrogen bond to a ribose group of the bound nucleotide.

![Complex I in the deactive state and under turnover conditions.\
The model for complex I in the deactive state (colour) is overlaid with the cryo-EM density (grey) for complex I under turnover conditions. There are no differences in overall structure, so there is no indication that the matrix arm moves relative to the membrane arm during turnover. Occupation and conformational changes of the substrate binding sites are shown in [Figure 13](#fig13){ref-type="fig"}.](elife-39213-fig12){#fig12}

![Substrate binding sites of complex I.\
(**A**) Under steady-state turnover conditions NADH (mesh, cryo-EM density) binds to the FMN cofactor and residues of the 51 kDa subunit; (**B**) ubiquinone binding site in the deactive state (mesh, cryo-EM density; 49 kDa subunit, green; PSST subunit, blue) and under steady-state turnover (**C**). The ubiquinone headgroup (purple) binds between the β1-β2 loop of the 49 kDa subunit and helix α2 of PSST. (**D**) This binding site overlaps with the position of the toxophore of decyl-quinazolineamine (orange) that was modelled based on anomalous diffraction of brominated inhibitor derivatives in the X-ray structure of *Y. lipolytica* complex I ([@bib51]).](elife-39213-fig13){#fig13}

In the 49 kDa subunit we observed a change in the structure of the β1-β2 loop of the N-terminal β sheet, which widens the central cavity formed by this subunit and subunit PSST. A clear density consistent with a ubiquinone head group was found between the 49 kDa subunit β1-β2 loop and the α2 helix of subunit PSST ([Figure 13B,C](#fig13){ref-type="fig"}). This position closely matches that of a ubiquinone-antagonistic inhibitor in the X-ray structure of *Y. lipolytica* complex I, as identified by anomalous scattering of bromine-substituted inhibitor ([Figure 13D](#fig13){ref-type="fig"}) ([@bib51]). We conclude that the new density represents the headgroup of a bound ubiquinone substrate at a minimal edge-to-edge distance of \~12 Å from cluster N2. This site is different from the ubiquinone binding site reported for the bacterial enzyme from *T. thermophilus*, which engages a strictly conserved tyrosine adjacent to the terminal iron-sulfur cluster N2 and positions the quinone headgroup \~2 Å closer to cluster N2 ([@bib6]) ([Figure 14A](#fig14){ref-type="fig"}). There is abundant evidence from site-directed mutagenesis in *Y. lipolytica* to support substrate and inhibitor binding to this tyrosine ([@bib44]), suggesting that this binding site also exists in the mitochondrial enzyme and that it alternates with the site observed in the structure of complex I under turnover conditions, as presented here.

![Alternating binding positions of ubiquinone support a two-state stabilization change mechanism for respiratory complex I ([@bib11]).\
(**A**) ubiquinone and Tyr144 of the 49 kDa subunit (stick representation) and the β1-β2 loop of the 49 kDa and helix α2 and FeS cluster N2 of the PSST subunit in the ubiquinone binding pocket of *Y. lipolytica* complex I (green) were superimposed on ubiquinone and the corresponding structures in *T. thermophilus* (grey). The position of ubiquinone in *T. thermophilus* (PDB ID: 4HEA) was fitted according to [Figure 4](#fig4){ref-type="fig"} in ([@bib6]). The position of ubiquinone in *T. thermophilus* is assigned to the E-state (**E**) while the position of ubiquinone determined in our study is assigned to the P-state (P). (**B**) Electron transfer from iron-sulfur cluster N2 occurs in the E-state (grey), while ubiquinone intermediates are protonated in the P-state (green). The stabilization of negatively charged redox intermediates of ubiquinone drive the transition from the E- to the P-state, changing the binding site for the ubiquinone headgroup. This would create conformational and electrostatic strain in the loops lining the ubiquinone binding pocket. (**C**) The strain provides the energy for a power stroke transmitted through a chain of titratable residues (orange) into the membrane arm, where it drives the proton pump modules (red dots) ([@bib51]).](elife-39213-fig14){#fig14}

Discussion {#s3}
==========

Two different models for the structural basis of the A/D transition of complex I have recently been proposed. In the X-ray structure of the deactive form of *Y. lipolytica* complex I ([@bib51]), access of a ubiquinone-antagonistic inhibitor into a binding position close to cluster N2 was blocked by a specific conformation of the β1-β2 loop of the 49 kDa subunit. We hypothesized that during the A/D transition the interface region of complex I can switch between two defined conformational states and that the A- and D-forms of complex I are tightly linked with intermediates of the catalytic cycle. In contrast, the 'unfolded Q site model' for the A/D transition ([@bib9]) describes the D-form as an 'off pathway' intermediate that is characterized by extensive relaxation of several loops in and around the ubiquinone binding cavity. According to this model, ubiquinone is required to restructure the interface region during transition into the A-form. Blaza *et al.* speculated that a corresponding loss of defined protein structure in the deactive *Y. lipolytica* complex I was prevented by a bound inhibitor molecule. However, this can now be excluded, as in our cryo-EM structure of *Y. lipolytica* complex I no inhibitor was present. Yet unfolding of the ubiquinone reduction site was not observed, at least not to an extent comparable to mammalian complex I. The species-dependent degrees of disorder in this critical region of complex I may reflect the significantly higher energy barrier for the A/D transition in bovine complex I as compared to *Y. lipolytica* ([@bib36]). It is interesting to note that in mouse complex I the interface between accessory subunits NDUFA5 and NDUFA10 changes during the A/D transition; strong contacts between the two subunits seem to selectively stabilize the A form ([@bib2]). This effect can be excluded for the *Y. lipolytica* complex, because it does not have an NDUFA10 ortholog.

Ubiquinone reduction releases the energy for proton translocation. The ubiquinone reduction site therefore has to play a central role in energy conversion. Our data provide direct evidence for our earlier proposal of a second binding site for ubiquinone within the substrate binding pocket of complex I ([@bib51]), which becomes dominant during steady-state turnover. As compared to the D-form, under turnover conditions the only notable difference observed nearby was a reorganization of the β1-β2-loop of the 49 kDa subunit ([Figure 13B,C](#fig13){ref-type="fig"}). The critical loop connecting TMH1 and TMH2 of ND3 is flexible in both states ([Figure 10](#fig10){ref-type="fig"}). These findings support our proposed integrated functional model, which suggests that the structural changes associated with the A/D transition and the catalytic cycle of complex I are in fact closely linked ([@bib51]). According to this model, the D-form represents the enzyme locked in an intermediate state of the catalytic cycle termed P-state in the proposed two-state stabilization-change mechanism ([@bib11]) ([Figure 14B](#fig14){ref-type="fig"}). The E-state would be characterized by a ubiquinone binding site closer to iron-sulfur cluster N2 ([Figure 14A](#fig14){ref-type="fig"}), which so far was observed only in the oxidized bacterial enzyme ([@bib6]) that does not undergo the A/D transition. A larger distance between the ubiquinone headgroup and its primary electron donor is in principle consistent with the impaired reduction in the P-state, as predicted by the mechanistic model. The observed 12 Å distance between the ubiquinone headgroup and cluster N2 in the P-state is within the \<14 Å range that would still allow efficient electron transfer according to the 'Moser-Dutton ruler' ([@bib38]) commonly used to estimate electron tunnelling rates between redox centres in proteins. However, in the present case, electron transfer is linked to protonation, and therefore other parameters, such as reorganization energy and packing density, have to be taken into consideration. These parameters do not depend simply on distance but on the local protein environment. They are likely to slow down electron transfer sufficiently for the mechanistic model we propose, even at the short distance observed for the P-state. Further studies and higher-resolution structures will be required to resolve this issue.

In the catalytic cycle, the E-state is predicted to be short-lived under the uncoupled steady-state turnover conditions applied here, explaining the observed predominance of the P-state. Once bound to the E-site, ubiquinone is rapidly reduced by iron sulfur-cluster N2, which essentially remains reduced on the time scale of catalytic turnover ([@bib32]) ([Figure 14B](#fig14){ref-type="fig"}). The resulting highly unstable semiquinone then rapidly triggers the E → P conversion, creating the alternate binding site for the ubiquinone headgroup ([@bib51]). These rearrangements are driven by thermodynamic stabilization of the charged ubiquinone intermediate that provides the energy for the electrostatic power stroke ([@bib11]). The power stroke is then transmitted through the chain of protonable residues into the membrane arm, where it ultimately drives proton pumping ([Figure 14C](#fig14){ref-type="fig"}). Subsequently, neutral semiquinone produced by protonation in the P-state allows the system to return to the E-state. The semiquinone then picks up the second electron to trigger another power stroke driven by the stabilization of the ubiquinol anion ([Figure 14B](#fig14){ref-type="fig"}).

In summary, our cryo-EM structure of mitochondrial complex I under turnover conditions corroborates several predictions of the proposed two-state stabilization change mechanism and how it relates to the regulatory A/D transition. Our new structure provides strong support for our integrated functional model that describes the structural basis of energy conversion and regulation in respiratory complex I.

Materials and methods {#s4}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource   Designation                  Source or reference    Identifiers                                                     Additional information
  ------------------------------------ ---------------------------- ---------------------- --------------------------------------------------------------- ------------------------
  Strain, strain\                      ∆mus51, lys1^-^, leu2^-^,\   PMID 24706851                                                                          
  background\                          ura3^-^, 30Htg2, ndh2i                                                                                              
  (*Y. lipolytica* GB20)                                                                                                                                   

  Strain, strain\                      derived from\                PMID 17267395                                                                          Prof. Robert\
  background\                          C43(DE3), ∆*cyoBCD*::kan                                                                                            B. Gennis,\
  (*E. coli* CLY)                                                                                                                                          University of Illinois

  Genetic reagent\                     cyoABCDE in\                 this work                                                                              Dr. Hao Xie,\
  (pET17b-V14)                         pET 17b                                                                                                             MPI for Biophysics,\
                                                                                                                                                           Frankfurt

  Chemical compound,\                  n-Dodecyl β-\                Glycon Biochemicals\   Cat. \# D97002-C                                                
  drug                                 maltoside                    GmbH                                                                                   

  Chemical compound,\                  Decylubiquinone              Sigma-Aldrich/Merck    Cat. \# D7911                                                   
  drug                                                                                                                                                     

  Chemical compound,\                  β-Nicotinamide\              Sigma-Aldrich/Merck    Cat. \# N8129                                                   
  drug                                 adenine dinucleotide                                                                                                

  Chemical compound,\                  Asolectin from\              Sigma-Aldrich/Merck    Cat. \# 11145                                                   
  drug                                 soybean                                                                                                             

  Chemical compound,\                  CHAPS, Anagrade              Anatrace               Cat. \# C316                                                    
  drug                                                                                                                                                     

  Software,\                           Coot                         PMID: 15572765         RRID: [SCR_014222](https://scicrunch.org/resolver/SCR_014222)   
  algorithm                                                                                                                                                

  Software,\                           CTFFIND4                     PMID:26278980                                                                          
  algorithm                                                                                                                                                

  Software,\                           Gctf                         PMID:26592709                                                                          
  algorithm                                                                                                                                                

  Software,\                           MolProbity                   PMID: 20057044         RRID: [SCR_14226](https://scicrunch.org/resolver/SCR_14226)     
  algorithm                                                                                                                                                

  Software,\                           MotionCor2                   PMID: 28250466                                                                         
  algorithm                                                                                                                                                

  Software,\                           Phenix                       PMID: 20124702         RRID: [SCR_014224](https://scicrunch.org/resolver/SCR_014224)   
  algorithm                                                                                                                                                

  Software,\                           PyMOL                        Schrödinger, LLC       RRID: [SCR_000305](https://scicrunch.org/resolver/SCR_000305)   
  algorithm                                                                                                                                                

  Software,\                           RELION                       PMID: 27845625         RRID: [SCR_016274](https://scicrunch.org/resolver/SCR_016274)   
  algorithm                                                                                                                                                

  Software,\                           UCSF Chimera                 PMID: 15264254         RRID: [SCR_004097](https://scicrunch.org/resolver/SCR_004097)   
  algorithm                                                                                                                                                

  Software,\                           TMHMM Server                 PMID: 11152613         RRID: [SCR_014935](https://scicrunch.org/resolver/SCR_014935)   
  algorithm                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Purification and characterization of respiratory complex I from *Yarrowia lipolytica* {#s4-1}
-------------------------------------------------------------------------------------

Cells were grown in a 10-liter Biostat C fermenter (Braun, Germany) under high aeration and broken with a glass bead mill cell‐disintegrator (Euler Biotechnologie, Germany). Mitochondrial membranes were isolated by differential centrifugation in 20 mM MOPS, pH 7.2, 600 mM sucrose, 1 mM EDTA. Complex I was purified in dodecyl maltoside (DDM) by His-tag affinity chromatography and gel filtration as described ([@bib28]) but with reduced detergent concentration in column buffers (0.025%) to preserve native lipids that are essential for enzyme activity. Under our standard assay conditions (60 µM DBQ, no added lipid or detergent) the preparation had an activity of 1.8 µMol^−1^mg^−1^min^−1^, increasing to 5.9 µMol^−1^mg^−1^min^−1^ upon lipid reactivation ([@bib17]). Using the assay conditions established for bovine complex I (200 µM DBQ, 0.15% asolectin, 0.15% CHAPS) ([@bib9]) the activity of the preparation was 13.9 µMol^−1^mg^−1^min^−1^.

Determination of lipids by mass spectrometry {#s4-2}
--------------------------------------------

Lipids of human erythrocytes were extracted with an MTBE protocol according to Matyash *et al*. ([@bib37]). Lipid extracts were resuspended in 1000 µl CHCl~3~/MeOH 1:1 and 12:0/13:0 PC, 17:0/20:4 PC, 14:1/17:0 PC, 21:0/22:6 PC, 12:0/13:0 PI, 17:0/20:4 PI, 14:1/17:0 PI, 21:0/22:6 PI (2 µM each) 17:1 LPC, (1.5 µM each), 12:0/13:0 PE, 17:0/20:4 PE, 14:1/17:0 PE, 21:0/22:6 PE, 12:0/13:0 PS, 17:0/20:4 PS, 14:1/17:0 PS, 21:0/22:6 PS (3 µM each), 14:1/14:1/14:1/15:1 CL (2.97 µM), 15:0/15:0/15:0/16:1 CL (2.70 µM), 22:1/22:1/22:1/14:1 CL (2.36 µM) and 24:1/24:1/24:1/14:1 CL (2.27 µM) were added as internal standard. 2 µl were injected on a Waters BEH C8, 100 × 1 mm, 1.7 µm HPLC column used with an Ultimate 3000 UHPLC (Thermo Scientific, USA). Solvent A was water with 1% ammonium acetate and 0.1% formic acid, and solvent B was acetonitrile/2-propanol 5:2 with 1% ammonium acetate and 0.1% formic acid. Gradient elution started at 50% mobile phase B, rising to 100% B over 40 min; 100% B were held for 10 min and the column was re-equilibrated with 50% B for 8 min before the next injection. The flow rate was 150 µl/min.

Data acquisition was performed according to Triebl *et al*. ([@bib45]) by Orbitrap-MS (LTQ-Orbitrap, Thermo Scientific) full scan in preview mode at a resolution of 100,000 and \<2 ppm mass accuracy with external calibration. The spray voltage was set to 4500 V and the capillary temperature was at 300°C. From the FT-MS preview scan the 10 most abundant *m/z* values were picked in data dependent acquisition (DDA) mode, fragmented in the linear ion-trap analyser and ejected at nominal mass resolution. Normalized collision energy was set to 50%, the repeat count was two and the exclusion duration was 10 s. Data were analysed by Lipid Data Analyzer, a custom-developed software tool described in detail by Hartler *et al.* ([@bib24]; [@bib25]) (<http://genome.tugraz.at/lda/lda_download.shtml>).

Construction of the expression vector of the cytochrome *bo*~3~ ubiquinol oxidase {#s4-3}
---------------------------------------------------------------------------------

Genomic DNA of *Vitreoscilla* sp. C1 was isolated using the G-spin genomic extraction kit (iNtRON Biotechnology, South Korea). A 4,836 bp DNA fragment containing the *cyoABCDE* operon was amplified by PCR using primers Vbo3-NdeI und Vbo3-HindIII. The PCR product was digested with NdeI and HindIII endonucleases and ligated into the same site of pET-17b (Novagen, Germany), resulting in pET-17b-Vbo3. A TEV cleavage site and a deca-histidine tag was introduced at the C-terminus of the CyoA subunit by the InFusion ligation-independent cloning method (Clontech, USA), for purification by metal affinity chromatography. Simultaneously, an artificial ribosomal binding site was inserted upstream of the translational start site of the *cyoB* gene. For InFusion Cloning, the primer pairs Vbo3-10/Vbo3-15 and Vbo3-19/Vbo3-20 were used. The resulting final construct pET17b-V14 was verified by sequencing and introduced into the *E. coli* expression strain. The primer sequences are listed in [Table 4](#table4){ref-type="table"}.

10.7554/eLife.39213.023

###### Oligonucleotides used in this work.

  ----------------------------------------------------------------------------
  Oligonucleotides   Sequence (5'−3')
  ------------------ ---------------------------------------------------------
  Vbo3-NdeI^a^       GCG[CATATG]{.ul}AAGCAGATGATTCAGGTC

  Vbo3-HindIII^a^    GGG[AAGCTT]{.ul}TC AAAAATAAATATGCGGCAAC

  Vbo3-10            TAATCTATGTTAGGTAAACTCGATTGG

  Vbo3-15            ATTTCCTCCTGCAGCAGATGCAGCAAC

  Vbo3-19^b^         GCTGCAGGAGGAAATGAAAACCTGTACTTTCAAGGTCATCACCATCACCATCAC\
                     CATCACCATCACTAAGCTGCATCTGCTGCAGGAGGAAATTAATCTATGTTAGGT

  Vbo3-20^b^         ACCTAACATAGATTAATTTCCTCCTGCAGCAGATGCAGCTTAGTGATGGTGATG\
                     GTGATGGTGATGGTGATGACCTTGAAAGTACAGGTTTTCATTTCCTCCTGCAGC
  ----------------------------------------------------------------------------

\*Restriction enzymes sites are underlined.

^‡^The nucleotide sequences encoding the TEV cleavage site and the deca-histidine tag are shown in red and blue, respectively. The artificial intergenic region containing the *Vitreoscilla* ribosomal binding site is shown in magenta.

Expression of the cytochrome *bo*~3~ ubiquinol oxidase {#s4-4}
------------------------------------------------------

Expression vector pET17b-V14 was transformed into *E. coli* strain CLY (kindly provided by Prof. Robert B. Gennis, University of Illinois), which lacks the endogenous cytochrome *bo*~3~ ubiquinol oxidase. A single colony was used to inoculate 50 ml of LB medium supplemented with 50 μg/mL kanamycin and 100 μg/mL carbenicillin. This pre-culture was grown at 37°C overnight and used to inoculate 2 liters of LB medium. The main culture was incubated at 30°C and 180 rpm until the optical density (OD) at 600 nm reached 0.6 -- 0.8. Production of *Vitreoscilla bo*~3~ ubiquinol oxidase was induced by addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and cultures were grown for 6 hr. Cells were harvested by centrifugation (10,500 × *g*, 4°C, 20 min) and resuspended in ice-cold resuspension buffer (50 mM potassium phosphate, pH 8.3, 5 mM MgCl~2~, 1 mM Pefabloc, DNase I) at a ratio of 5 ml of buffer per 1 g of wet cells. Cells were disrupted four times by passing through an M-110LA microfluidizer (Microfluidics) on ice at 8,000 psi. Cell debris was removed by centrifugation (14,000 × *g*, 4°C, 1 hr). Membrane vesicles were collected from the supernatant by ultracentrifugation (214,000 × *g*, 4°C, 3 hr), flash-frozen in liquid nitrogen and stored at −80°C prior to solubilization.

Purification of the cytochrome *bo*~3~ ubiquinol oxidase {#s4-5}
--------------------------------------------------------

Crude membranes were resuspended in solubilization buffer (50 mM potassium phosphate, pH 8.3, 100 mM NaCl, 1 mM Pefabloc) at a ratio of 10 ml of buffer per 1 g of membrane. The total protein concentration was determined by the BCA assay (Pierce, USA) according to manufacturer's instructions. Membrane proteins were solubilized by moderate stirring of resuspended membranes with 2.5 mg DDM (GLYCON Biochemicals, Germany) per mg of protein at 4°C for 1 hr. The insoluble membrane fraction was removed by ultracentrifugation (214,000 × *g*, 4°C, 1 hr) and the supernatant containing solubilized membrane proteins was filtered through a 0.45 μm polyethersulfone (PES) membrane.

*Vitreoscilla bo*~3~ ubiquinol oxidase was purified in three chromatographic steps using an ÄKTApurifier system (GE Healthcare, USA), including Ni^2+^-NTA affinity, Q-Sepharose anion exchange and Superdex 200 gel filtration chromatography. Prior to affinity capture, imidazole was added to the solubilized membrane solution to a final concentration of 20 mM. Solubilized protein was loaded onto a Ni^2+^-NTA column, equilibrated with 50 mM potassium phosphate, pH 8.3, 100 mM NaCl, 20 mM imidazole, 0.05% DDM. The column was washed with equilibration buffer until the A~280~ and A~410~ returned to baseline levels. Bound protein was eluted with Ni^2+^-NTA elution buffer (50 mM potassium phosphate, pH 8.3, 100 mM NaCl, 150 mM imidazole, 0.05% DDM). Eluate fractions were pooled and diluted two-fold with 50 mM potassium phosphate, pH 8.3, 0.05% DDM, and loaded onto a Q-Sepharose high performance column pre-equilibrated with 20 mM Tris-HCl, pH 7.5, 0.03% DDM. After extensive washing, the protein was eluted with a linear 5 to 400 mM NaCl gradient in 20 mM Tris-HCl, pH 7.5, 0.03% DDM. Red-colored fractions were collected and concentrated using Amicon Ultra-15 concentrators (100K MWCO, Merck Millipore, Germany). The concentrated protein was purified further by chromatography on a Superdex 200 column equilibrated in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.03% DDM. Peak fractions containing the cytochrome *bo*~3~ ubiquinol oxidase from *Vitreoscilla* were collected and concentrated to a final concentration of \~200 μM and stored at −80°C.

In vitro assay of a minimal respiratory chain {#s4-6}
---------------------------------------------

Oxygen consumption was determined polarographically with a Clark-type oxygen electrode (OX-MR; Unisense, Denmark) connected to a picoammeter (PA2000 Multimeter; Unisense, Denmark). Analog signals were converted into digital with an A/D converter (ADC-216; Unisense, Denmark) and then recorded with the software Sensor Trace Basic 2.1 supplied by the manufacturer.

In vitro assays of a minimal respiratory chain consisting of complex I and quinol oxidase were performed in 2 ml glass vials while stirring in a water bath at 18°C. The reaction vial was filled with 50 mM Tris-HCl, pH 7.5, 100 mM NaCl and 0.02% DDM, followed by the addition of 200 μM n-decylubiquinone (DBQ), 2 μM complex I and 1 μM cytochrome *bo*~3~ ubiquinol oxidase (complex IV) to a final volume of 600 μl. The reaction was then initiated by adding 2 mM reduced nicotinamide adenine dinucleotide (NADH), and inhibited by the addition of 2-decyl-4-quinazolinyl amine (DQA) or potassium cyanide (KCN).

Cryo-EM {#s4-7}
-------

Deactive complex I was diluted to a final protein concentration of 2 μM in 20 mM Tris-HCl, pH 7.2, 100 mM NaCl, 1 mM EDTA and 0.025% DDM. For cryo-EM under turnover, 4 μM of complex I incubated with 400 μM DBQ was mixed 1:1 with 2 μM *bo*~3~-type ubiquinol oxidase, tobacco mosaic virus as a spreading agent (0.13 mg/ml) and 4 mM NADH. 3 μl of the mixture was applied to freshly glow-discharged C-flat 1/1 holey carbon grids (Protochips, USA), automatically blotted (70% humidity, blot time 5 -- 8 s, drain and wait time 0 s, blot force −2 a.u.) and flash-frozen in liquid ethane in an FEI Vitrobot ^TM^ Mark IV (FEI NanoPort, the Netherlands). Cryo-EM data of inactive complex I were collected automatically with Leginon ([@bib43]) on a FEI Tecnai Polara at 300 kV equipped with a Gatan K2 direct electron detector operating in counting mode. Videos were collected at a total exposure of 60 e^-^/Å^2^, at defocus values of −1.5 to −3.0 μm with a calibrated pixel size of 1.09 Å (200,000x). Cryo-EM images of complex I under turnover conditions were collected on a 300 kV FEI Titan Krios on a Falcon III direct electron detector operating in counting mode. Images were collected automatically with EPU software at a nominal magnification of 75,000x with a calibrated pixel size of 1.053 Å and a total exposure of 30 -- 40 e^-^/Å^2^, at a nominal defocus of −1.5 to −4.5 μm.

Image processing {#s4-8}
----------------

A set of 3110 micrographs of deactive complex I and 5650 micrographs of complex I under turnover conditions were motion-corrected and dose-weighted with MotionCor2 ([@bib49]) ([Figure 1A](#fig1){ref-type="fig"}). For deactive complex I, the micrograph-based contrast transfer function (CTF) was determined with CTFFIND4 ([@bib41]). Particles were picked using Autopick within the RELION2.1 workflow ([@bib29]), yielding 271,443 particles extracted in boxes of 456 × 456 pixels. Particles were subjected to initial reference-free two-dimensional (2D) classification in RELION2.1 to remove imperfect particles. Visual selection of class averages with interpretable features resulted in a dataset of 269,508 particles. These were used for 3D classification with a previous cryo-EM map of complex I from *Y. lipolytica* ([@bib16]) low-pass filtered to 40 Å as an initial model. A good class of 124,626 particles was used for auto-refinement and particle polishing in RELION2.1. After refinement the post-processing procedure implemented in RELION2.1 was applied to the final map for B-factor sharpening and resolution validation ([@bib14]). The final map used for model building had a resolution of 4.3 Å, and was sharpened using an isotropic B-factor of −142 Å ([Figure 2A](#fig2){ref-type="fig"}, [Table 1](#table1){ref-type="table"}). Local map resolution was estimated with ResMap (<http://resmap.sourceforge.net>) ([@bib34]) ([Figure 2](#fig2){ref-type="fig"}). To identify the ST1 subunit ([@bib16]), the map was subjected to a final round of 3D classification and a 3D class displaying an extra density protruding from the side of the matrix arm was used for a refinement which resulted in a map of 5.2 Å resolution from 36,723 particles ([Figure 1A](#fig1){ref-type="fig"}).

For complex I under turnover conditions, CTF parameters were estimated by Gctf ([@bib48]). Particles were picked automatically using 2D-class averages from the deactive complex I dataset for reference. The initial set of 273,581 particles extracted in boxes of 450 × 450 pixels was subjected to reference-free 2D classification in RELION2.1 to remove imperfect particles and *bo*~3~-type ubiquinol oxidase. The remaining 257,951 particles were sorted by 3D classification and the map from inactive complex I low-pass filtered to 40 Å was used as initial model. The best class of 115,083 particles was subjected to auto-refinement and particle polishing in RELION2.1. The final map of 4.5 Å resolution was sharpened with an isotropic B-factor of −215 and the local resolution was estimated with ResMap.

Model building {#s4-9}
--------------

Homology models of individual subunits from *Y. lipolytica* complex I were created by SWISS-MODEL ([@bib8]) based on cryo-EM structures of *B. taurus* class 1 (PDB ID: 5LDW), *B. taurus* class 2 (PDB: 5LC5), *O. aries* (PDB ID: 5LNK), and the crystal structure of *Y. lipolytica* complex I (PDB ID: 4WZ7). Rigid body fitting into the cryo-EM map was performed with Chimera ([@bib39]). The resulting model was adjusted to the density or manually built in COOT ([@bib18]). Secondary structure predictions using the TMHMM server ([@bib33]) and well-resolved side chain densities guided model building ([Figure 3](#fig3){ref-type="fig"}). The model was refined in PHENIX ([@bib1]) using phenix.real_space_refinement for six macro-cycles followed by several rounds of rebuilding in COOT. A quality check with MolProbity ([@bib13]) indicated excellent stereochemistry with 85.83% of the non-glycine and non-proline residues found in the most-favoured region and 0.74% outliers (all-atom clashscore: 8.55). The model was cross-validated against overfitting by refinement in one half map ([@bib12]) and showed no evidence of overfitting. Refinement and validation statistics are summarized in [Table 1](#table1){ref-type="table"}. Figures were drawn with Chimera ([@bib39]) and PyMOL (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger, LLC).
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###### Coordinate file of complex I under steady-state turnover conditions with NADH and ubiquinone binding sites occupied (compare EMD-4385).

Please note that the position of the ubiquinone head group was identified but that the precise orientation of the molecule in the site remained ambiguous due to limited detail of the 4.5 Å resolution map.

10.7554/eLife.39213.025

Data availability {#s7}
-----------------

The cryo-EM structure of deactive complex I has been deposited in the PDB with PDB ID 6GCS and the cryo-EM maps of deactive complex I and under turnover in the EMDB under accession numbers EMD-4384 and EMD-4385. The coordinate file of complex I under steady-state turnover conditions with NADH and ubiquinone binding sites occupied has been provided as Supplementary file 1. Please note that the position of the ubiquinone head group was identified but that the precise orientation of the molecule in the site remained ambiguous due to limited detail of the 4.5 Å resolution map.

The following datasets were generated:

Kristian PareyJanet Vonck2018cryo-EM structure of respiratory complex I from Yarrowia lipolytica<http://www.ebi.ac.uk/pdbe/entry/pdb/6gcs>Publicly available at the Electron Microscopy Data Bank (accession no: 6GCS)

Kristian PareyJanet Vonck2018CRYOEM STRUCTURE OF RESPIRATORY COMPLEX I FROM YARROWIA LIPOLYTICA<http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-4384>Publicly available at the Electron Microscopy Data Bank (accession no: EMD-4384)

Kristian PareyJanet Vonck2018CRYOEM STRUCTURE OF RESPIRATORY COMPLEX I FROM YARROWIA LIPOLYTICA UNDER TURNOVER<http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-4385>Publicly available at the Electron Microscopy Data Bank (accession no: EMD-4385)

The following previously published datasets were used:

Vinothkumar KRZhu JHirst J2016Structure of mammalian respiratory Complex I, class1<https://www.rcsb.org/structure/5LDW>Publicly available at the RCSB Protein Data Bank (accession no: 5LDW)

Vinothkumar KRZhu JHirst J2016Structure of mammalian respiratory Complex I, class2<https://www.rcsb.org/structure/5LC5>Publicly available at the RCSB Protein Data Bank (accession no: 5LC5)

Fiedorczuk KLetts JAKaszuba KSazanov LA2016Entire ovine respiratory complex I<https://www.rcsb.org/structure/5LNK>Publicly available at the RCSB Protein Data Bank (accession no: 5LNK)

Wirth CZickermann VBrandt UHunte C2015Crystal structure of mitochondrial NADH:ubiquinone oxidoreductase from Yarrowia lipolytica<https://www.rcsb.org/structure/4WZ7>Publicly available at the RCSB Protein Data Bank (accession no: 4WZ7)

Baradaran RBerrisford JMMinhas GSSazanov LA2013Crystal structure of the entire respiratory complex I from Thermus thermophilus<https://www.rcsb.org/structure/4HEA>Publicly available at the RCSB Protein Data Bank (accession no: 4HEA)
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The cryo-EM structure of respiratory complex I at work\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Sjors HW Scheres as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Marten Wikstrom (Reviewer \#2); Vinoth Kumar (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript describes the structures of Yeast Complex I in its deactive state and in a state where the enzyme is performing catalysis thereby supporting a two-state stabilization change mechanism. The structure (higher-resolution than the previous) of yeast complex I now joins other complex I structures from different species determined by cryo-EM in recent times. The manuscript merits publication as the yeast complex I has a few salient features (additional/different subunits -- useful for understanding the evolution of the enzyme and the role of these subunits), and it represents the first observation of a ubiquinone derivative bound to the enzyme, identifying a site different from that inferred from other studies. The following suggestions would improve the manuscript.

Essential revisions:

1\) The authors\' presentation of a possible mechanism of proton pumping would do well by acknowledging that Euro et al., (2008) were the first to suggest that the negative charge of an anionic form of either semi-ubiquinone or ubiquinol would start an essentially electrostatic coupling mechanism that would spread from the site of Q reduction to the proton pump centers in the membrane domain.

2\) The authors should give the edge-to-edge distance between the quinone in the observed binding site and the Fe/S center N2, and/or the tyrosine close to the latter. If this distance is significantly less than \~14Å some new thinking may be required.

3\) The recent structures of mouse enzyme (Agip et al. 2018, NSMB), where the authors have imaged the complex in defined biochemical states shows that there might be distinct states in Complex I. On this context, I feel that in the current manuscript this should be discussed and not be biased in their interpretation that no large structural change occurs (the relative position of matrix/membrane arm). While it might still be true that large structural changes might not be required, the presence of detergent environment (though lipids are present) and the possibility that the ubiquinone might exit through a different pathway than the entry should be considered.

4\) The authors say that they observed only one major class (Results section) indicating a homogenous state but the resolution they have obtained is lower than that reported for mammalian complex I. This kind of contradicts the statement in Discussion section as they argue that the unfolding (more appropriate will be disorder) and change in orientation in bovine enzyme is due to lesser stability when released from supercomplex. If the yeast enzyme was homogenous then the resolution should have been better! In addition, the mouse Complex I reveals a resolution of 3.3 Å with \~1/10th of particles used in the yeast enzyme preparation. The number of particles used for reconstruction for the current structures seem to imply that there is something happening during the biochemical procedure and or grid. This may warrant some discussion.

5\) The authors make a point of their model being more complete than the previously available X-ray structure. But how can the authors be sure about assigning all the accessory sub-units at these resolutions? How much ambiguity still exists? Supplementary figures with zoomed views of density features that make each subunit\'s assignment unique should be added to remove doubts about ambiguity of the assignments. Or if some ambiguities remain, these should be mentioned clearly in the text.

6\) Refinement of the atomic models is cumbersome at these resolutions. Overfitting is a real possibility. To show that the model is not overfitting the map, the authors should scramble and then re-refine the model in one of the half-maps, and subsequently calculate FSC curves of that refined model with both of the half-maps. A supplementary figure of these curves should be added to the paper. The curves should not be far from each other (which happens if the model overfits the data). If they are, the weight on the cryo-EM density relative to the restraints should be lowered, and the final model (which can still be refined in the combined, final map) should be re-refined with those weights.

7\) Provided model refinement can be done without too much overfitting, the model for the turnover map could be refined and both the map and the model could be deposited. The refinement statistics should then also be added to the relevant table. This is because, the deactive state will not have the DBQ modelled and if a reader wants to study/probe/understand the binding site the only option is Figure 13 (as the authors have themselves found in Baradaran et al., 2013, where binding site is depicted in the figure but there is no map deposited).

8\) A normalised difference map (at a given σ threshold) might be useful to show the density for DBQ. As there are no major changes this should come out very nicely.

9\) It may be useful to show/define which of the states of mammalian complex I best matches with the yeast Complex I. There is an overlay of yeast X-ray and bovine deactive EM model in Figure 5C but its relevance is not mentioned either in the main text or the legend. I don\'t see a reason why this should be shown. Instead, an overlay of EM derived models of yeast deactive and mammalian (bovine or mouse) active/deactive might be informative.
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Author response

> Summary:
>
> This manuscript describes the structures of Yeast Complex I in its deactive state and in a state where the enzyme is performing catalysis thereby supporting a two-state stabilization change mechanism. The structure (higher-resolution than the previous) of yeast complex I now joins other complex I structures from different species determined by cryo-EM in recent times. The manuscript merits publication as the yeast complex I has a few salient features (additional/different subunits -- useful for understanding the evolution of the enzyme and the role of these subunits), and it represents the first observation of a ubiquinone derivative bound to the enzyme, identifying a site different from that inferred from other studies. The following suggestions would improve the manuscript.
>
> Essential revisions:
>
> 1\) The authors\' presentation of a possible mechanism of proton pumping would do well by acknowledging that Euro et al., (2008) were the first to suggest that the negative charge of an anionic form of either semi-ubiquinone or ubiquinol would start an essentially electrostatic coupling mechanism that would spread from the site of Q reduction to the proton pump centers in the membrane domain.

A central role of semiquinone for energy conversion was suggested before, but indeed Euro et al., were the first to propose electrostatic energy transfer to the membrane. We have added the reference to the manuscript.

> 2\) The authors should give the edge-to-edge distance between the quinone in the observed binding site and the FeS center N2, and/or the tyrosine close to the latter. If this distance is significantly less than \~14Å some new thinking may be required.

The edge-to-edge distance between the fitted ubiquinone molecule and FeS cluster N2 is approximately 12 Å, while the corresponding distance for the alternative position found in Thermus thermophilus is approximately 10 Å. We are aware that according to the "Dutton ruler" the binding position for ubiquinone determined here under steady state turnover conditions is within the 14 Å limit generally accepted for efficient electron transfer. However, the "Dutton ruler" does not strictly apply in our situation, because it refers to electron tunneling rates between metal centers in proteins, whereas the reduction of an organic molecule (ubiquinone) involves redox chemistry, which would not have the same, simple distance dependence. We therefore do not see any contradiction between the 12 Å distance and our proposed model that assigns this binding position to the P state. In the Results section of the revised manuscript, we state the 12 Å distance between cluster N2 and ubiquinone:

"We conclude that the new density represents the headgroup of a bound ubiquinone substrate at a minimal edge-to-edge distance of approximately 12 Å from cluster N2. This site is different from the ubiquinone binding site reported for the bacterial enzyme from Thermus thermophilus, which engages a strictly conserved tyrosine adjacent to the terminal iron-sulfur cluster N2 and positions the quinone headgroup about 2 Å closer to cluster N2 (Baradaran et al., 2013) (Figure 14A)."

We also added a short paragraph to the Discussion section to explain our reasoning as follows:

"A larger distance between the ubiquinone headgroup and its primary electron donor is in principle consistent with the impaired reduction in the P-state, as predicted by the mechanistic model. \[...\] They are likely to slow down electron transfer sufficiently for the mechanistic model we propose, even at the short distance observed for the P-state. Further studies and higher-resolution structures will be required to resolve this issue."

> 3\) The recent structures of mouse enzyme (Agip et al. 2018, NSMB), where the authors have imaged the complex in defined biochemical states shows that there might be distinct states in Complex I. On this context, I feel that in the current manuscript this should be discussed and not be biased in their interpretation that no large structural change occurs (the relative position of matrix/membrane arm). While it might still be true that large structural changes might not be required, the presence of detergent environment (though lipids are present) and the possibility that the ubiquinone might exit through a different pathway than the entry should be considered.

We agree that the very recent NSMB paper by Agip et al., deserves to be cited. Please note that this paper appeared after our manuscript was submitted. The major differences between the deactive forms of *Y. lipolytica* and bovine complex I were already discussed in our original manuscript. We can now generalize our conclusions on the mammalian enzyme, as the unfolding patterns of loops in the deactive forms of bovine and mouse complex I are very similar.

We did not intend to say that distinct states do not exist in complex I. In fact, we compare two different functional states. Concerning the question of large conformational changes, we find that the relative orientation of the two arms does not appear to change in *Y. lipolytica*, whereas such a movement is now consistently observed in two mammalian species. Therefore, we omitted our speculation that a change in relative orientation of the two arms might be a stability issue and related to the release of complex I from the supercomplex. Overall, the differences observed between bovine, mouse, and yeast complex I substantiate our previous conclusion that the species-dependent degrees of disorder reflect the significantly higher energy barrier for the A/D transition in mammalian complex I. Interestingly, a comparison of our structure to that from mouse in the active and deactive form offers a straightforward explanation for this remarkable difference. We added a short paragraph to the Discussion to point this out:

"It is interesting to note that in complex I from mouse the interface between accessory subunits NDUFA5 and NDUFA10 changes during the A/D transition and strong contacts between the two subunits seem to selectively stabilize the A form (Agip et al., 2018). This effect can be excluded for the *Y. lipolytica* complex, because it does not have a NDUFA10 ortholog."

We feel that in the absence of unequivocal data a further discussion of possible ubiquinone entry and exit pathways would be speculative and beyond the scope of this manuscript.

> 4\) The authors say that they observed only one major class (Results section) indicating a homogenous state but the resolution they have obtained is lower than that reported for mammalian complex I. This kind of contradicts the statement in Discussion section as they argue that the unfolding (more appropriate will be disorder) and change in orientation in bovine enzyme is due to lesser stability when released from supercomplex. If the yeast enzyme was homogenous then the resolution should have been better! In addition, the mouse Complex I reveals a resolution of 3.3 Å with \~1/10th of particles used in the yeast enzyme preparation. The number of particles used for reconstruction for the current structures seem to imply that there is something happening during the biochemical procedure and or grid. This may warrant some discussion.

In contrast to mammalian complex I, we see only one major class in the data without variability of the angle between the two arms. There are several reasons why the resolution of our maps is less high than that of the mouse map. The data for the deactive map was recorded on the Polara electron microscope, which is less stable than the Krios and therefore the data are slightly less good. The turnover data were collected on a Krios, but image contrast was reduced by the high concentrations of substrates in the sample.

> 5\) The authors make a point of their model being more complete than the previously available X-ray structure. But how can the authors be sure about assigning all the accessory sub-units at these resolutions? How much ambiguity still exists? Supplementary figures with zoomed views of density features that make each subunit\'s assignment unique should be added to remove doubts about ambiguity of the assignments. Or if some ambiguities remain, these should be mentioned clearly in the text.

We added two supplementary figures to show that the assignments are unambiguous, and changed the paragraph on accessory subunits (see below).

> 6\) Refinement of the atomic models is cumbersome at these resolutions. Overfitting is a real possibility. To show that the model is not overfitting the map, the authors should scramble and then re-refine the model in one of the half-maps, and subsequently calculate FSC curves of that refined model with both of the half-maps. A supplementary figure of these curves should be added to the paper. The curves should not be far from each other (which happens if the model overfits the data). If they are, the weight on the cryo-EM density relative to the restraints should be lowered, and the final model (which can still be refined in the combined, final map) should be re-refined with those weights.

We are pleased to add the result of this validation test in a new supplement to Figure 3. The curves do not indicate any overfitting.

> 7\) Provided model refinement can be done without too much overfitting, the model for the turnover map could be refined and both the map and the model could be deposited. The refinement statistics should then also be added to the relevant table. This is because, the deactive state will not have the DBQ modelled and if a reader wants to study/probe/understand the binding site the only option is Figure 13 (as the authors have themselves found in Baradaran et al., 2013, where binding site is depicted in the figure but there is no map deposited).

We deposited the map and the model for the deactive form and the map for complex I under turnover conditions. Obviously, at 4.5 Å resolution the ubiquinone molecule cannot be fitted precisely. Since inexperienced readers will not be aware of this, we prefer not to deposit the model with fitted UQ in the PDB for the time being. The 4.5 Å resolution map has been supplied as Supplementary file 1.

> 8\) A normalised difference map (at a given σ threshold) might be useful to show the density for DBQ. As there are no major changes this should come out very nicely.

The density for the Q in the difference map is weak because the site is either not fully occupied or the ubiquinone molecule is flexible. However, the Q site shows positive density at every stage of refinement for the structure under the turnover conditions, whereas this is not the case for the deactive state, indicating that the density is real. An overlay of the two maps is shown in [Author response image 1](#respfig1){ref-type="fig"}.

![Density for ubiquinone headgroup.\
View from the membrane arm into the ubiquinone binding pocket. Overlay of density maps (deactive, blue; turnover conditions, red; model for complex I under turnover conditions). Note that the blue map has slightly higher resolution and that the b1 b2 loop changes between the two states.](elife-39213-resp-fig1){#respfig1}

> 9\) It may be useful to show/define which of the states of mammalian complex I best matches with the yeast Complex I. There is an overlay of yeast X-ray and bovine deactive EM model in Figure 5C but its relevance is not mentioned either in the main text or the legend. I don\'t see a reason why this should be shown. Instead, an overlay of EM derived models of yeast deactive and mammalian (bovine or mouse) active/deactive might be informative.

Figure 5C is an overlay of the yeast X-ray structure with our deactive yeast EM map, not with the bovine map. The point of the figure is to show that the EM and X-ray structures of the same complex are consistent. We have clarified this in the legend. Fitting yeast to mammalian complex I is complicated because of a rotation of the two arms relative to one another, so that neither of them match.
